Antibiotic removal during kidney therapy in the ICU
Part of Infections clinical trials.
This trial studies how much certain antibiotics (meropenem, linezolid, and daptomycin) are removed when you're on a special blood-filtering machine called continuous renal replacement therapy (CRRT) for severe kidney injury. The results could help doctors give the right dose of antibiotics to treat infections effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe acute kidney injury (stage 3) and need continuous renal replacement therapy (CRRT)
- You are receiving at least one of these antibiotics: meropenem, linezolid, or daptomycin
- You must be 18 years old or older
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at how a special kidney filter called oXiris helped patients in the ICU who had septic shock (a life-threatening blood infection) and kidney failure. Researchers want to understand if this filter improved survival and recovery compared to standard treatment.
This trial tests a specific type of blood-filter treatment in critically ill ICU patients who have acute kidney injury and/or failure of other organs. It aims to see whether these filters can improve care by supporting kidney function and/or calming harmful inflammation.
This study looks at an add-on blood-filter treatment used in the ICU to help remove harmful substances like waste products, inflammation signals, or toxins from the blood. Results may help doctors understand whether this approach improves care and how it should be used.
This trial studies how common antibiotics move through the body when someone is on kidney replacement therapy (dialysis), including when dialysis starts during treatment. The results may help doctors choose the right antibiotic dose and timing for better infection treatment.
This study looks at how well a continuous kidney replacement therapy removes a common antibiotic combination (piperacillin and tazobactam) from the blood in intensive care patients. It may help doctors better dose the antibiotic for patients on this type of dialysis.
This trial tests a special device that filters parts of the blood to calm inflammation in people with severe acute kidney injury in the ICU. It may help improve recovery and reduce complications by “deactivating” certain immune cells.
Hear when a new Septic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.